Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 4, 2007, Pages 303-311

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ARGININE; ASENAPINE; BORTEZOMIB; BUCINDOLOL; CERTOLIZUMAB PEGOL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DASATINIB; DENOSUMAB; DESVENLAFAXINE; EPIGALLOCATECHIN GALLATE; ESOMEPRAZOLE; GANCICLOVIR; HOMOHARRINGTONINE; HYALURONIC ACID; MEPOLIZUMAB; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NILOTINIB; OBLIMERSEN; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETAPAMULIN; ROSIGLITAZONE; SARCOSINE; SCIO 469; SORIVUDINE; TIPIFARNIB; URACIL; VILDAGLIPTIN;

ARTICLE; ATHEROSCLEROSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RESEARCH; ESOPHAGITIS; HERPES ZOSTER; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMPETIGO; LUNG NON SMALL CELL CANCER; LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RHEUMATOID ARTHRITIS; ROSACEA; SCHIZOPHRENIA; SKIN DISCOLORATION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; HUMANS;

EID: 34547646007     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Shear, N., Gleich, G., Leiferman, K., Ring, J. Rationale and design of a placebo-controlled trial to evaluate the steroid-sparing effects of anti-IL5 monoclonal antibody (mepolizumab): Focus on cutaneous outcomes in patients with hypereosinophilic syndrome (HES). J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P716.
2. Fluture, A., Giugliano, G.R., Southard, M.C. et al. Angiographic outcomes in patients with non-STE ACS undergoing PCI using adjunctive recombinant nematode anticoagulant protein c2 versus placebo: An ANTHEM-TIMI 32 angiographic core lab analysis. Am J Cardiol 2006, 98(8, Suppl.): Abst TCT-506.
3. Mitchell, A., Detmer, N., Rushentsova, U., Philipp, T. Effects of ET-1 antagonism on ET-1-mediated vasoconstriction in the skin microcirculation of obese patients with atherosclerosis. J Hypertens 2006, 24(Suppl. 4): Abst P12.186.
4. Nasr, I.A., Bouzamondo, A., Hulot, J.S., Dubourg, O., Le Heuzey, J.Y., Lechat, P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis. Eur Heart J 2007, 28(4): 457.
5. de Berrazueta, J.R., González, J.P., de Mier, I., Poveda, J.J., García-Unzueta, M.T. Vasodilatory action of loop diuretics: A plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. J Cardiovasc Pharmacol 2007, 49(2): 90.
6. Sefton, J., Parizadeh, D., Lee, E. et al. A novel next-generation proton pump inhibitor (AGN 201904-Z) with a long plasma residence time provides more prolonged gastric acid inhibition than esomeprazole. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 124.
7. Stein, M.L., Collins, M.H., Villanueva, J.M. et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118(6): 1312.
8. Beutner, K., Jones, T., Bucko, A., Loss, R. A randomized, double-blind vehicle-controlled, multi-center study to evaluate the safety and efficacy of topically applied AN0128 cream, 1% for the treatment of mild to moderate atopic dermatitis. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P717.
9. Mendoza, N., Arora, A., Rady, P., Tyring, S. A phase II, placebo-controlled, safety, efficacy, and absorption evaluation of 3% sorivudine cream in herpes zoster. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P1902.
10. Markowitz, M., Morales-Ramirez, J.O., Nguyen, B.Y. et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006, 43(5): 509.
11. Oranje, A., Van der Wouden, J., Koning, S., Chosidow, O. Retapamulin ointment for the treatment of impetigo in adults and children: Results of a phase III, placebo-controlled, double-blind trial. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P16.
12. Beuner, K., Toledo-Bahena, M., Mata-Lara, M., Barbosa-Alanis, H. Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solution for the treatment of onychomycosis of the great toenail. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P1802.
13. Beutner, K., Sanders, V., Hold, K., Bullington, R. An open-label, multiple-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P1823.
14. Rosenstock, J., Baron, M.A., Dejager, S., Mills, D., Schweizer, A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 2007, 30(2): 217.
15. Fife, C., Mader, J.T., Stone, J. et al. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Wound Repair Regen 2007, 15 (1): 23.
16. Lane, N.E., Iannini, M., Atkins, C. et al. RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(9, Suppl.): Abst 451.
17. Dore, R., Hurd, E., Palmer, W. et al. Denosumab Increases bone mineral density in patients with Rheumatoid arthrities. Arthritis Rheum 2006, 54(9, Suppl.): Abst 488.
18. Riely, G.J., Gadgeel, S., Rothman, I. et al. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer (Ireland) 2007, 55(2): 181.
19. Garcia, J.A., Magi-Galluzzi, C., Rothaermel, J. et al. Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy. J Clin Oncol 2006, 24(18, Suppl.): Abst 4564.
20. Atasoy, B.M., Abacioglu, U., Ozgen, Z. et al. Adjuvant concomitant administration of uracil-tegafur (UFT) and folinic acid (FA) during irradiation for locally advanced rectum cancer: Tolerability assessment. Ann Oncol 2006, 17(Suppl. 9): Abst 401.
21. Giles, F., Rizzieri, D., Karp, J. et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007, 25(1): 25.
22. O'brien, S., Moore, J.O., Boyd, T.E. et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007, 25(9): 1114.
23. De Lima, M.J., Jabbour, E., Cortes, J. et al. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients (pts) with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. J Clin Oncol 2006, 24(18, Suppl.): Abst 16515.
24. Quintás-Cardama, A., Kantarjian, H., Garcia-Manero, G. et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007, 109(2): 248.
25. Perrine, S.P., Hermine, O., Small, T. et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109(6): 2571.
26. Witzig, T.E., Maurer, M.J., Johnston, P.B. et al. Oral tipifarnib (R115777) has single agent anti-tumor activity in patients with relapsed aggressive non-Hodgkin lymphoma (NHL): Results of a phase (II) trial in the university of Iowa/Mayo clinic lymphoma SPORE (CA97274). Blood 2006, 108(11): Abst 530.
27. Sullivan, D., Singhal, S., Schuster, M., Berenson, J. et al. A phase II study of PXD101 in advanced multiple myeloma. Blood 2006, 108(11): Abst 3583.
28. Chanan-Khan, A.A., Jaganath, S., Schlossman, R.L. et al. Phase I study of BB-10901 (huN901-DM1) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. Blood 2006, 108(11): Abst 3574.
29. Siegel, S.D., Krishnan, A., Lonial, S. et al. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood 2006, 108(11): Abst 3580.
30. Lerner, A. et al. Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: Interim report of a phase II multicenter study. Blood 2006, 108(11): Abst 2468.
31. Christine, C., Starr, P.A., Larson, P. et al. Aromatic l-amino acid decarboxylase gene transfer therapy for Parkinson's disease: Initial results of an open-label, dose escalation, safety and tolerability study. Mov Disord 2006, 21(Suppl. 15): Abst P256.
32. Elston, G.E., Johnston, G.A., Mortimer, N.J., Harman, K.E. Acute generalized exanthematous pustulosis associated with azathioprine hypersensivity. Clin Exp Dermatol 2007, 32(1): 52.
33. Liebowitz, M., Yeung, P., Olszyk, K., Entsuah, R. A randomized, double-blind, placebo-controlled trial of flexible-dose desvenlafaxine succinate in adult outpatients with major depressive disorder. Neuropsychopharmacology 2006, 31(Suppl. 1): S223.
34. Potkin, S.G., Fleming, K., Binneman, B., Keller, D.S., Alphs, L., Panagides, J. Asenapine cognitive function effects in acute schizophrenia: A placebo- and risperidone-controlled trial. Neuropsychopharmacology 2006, 31 (Suppl. 1): S251.
35. Tsai, G.E., Hsien-Yuan, L. Sarcosine (N-methylglycine) treatment for acute schizophrenia. Neuropsychopharmacology 2006, 31 (Suppl. 1): S126.
36. Incyclinide shows dose-response relationship in acne. DailyDrug News.com (Daily Essentials), 2007.
37. Syed, T., Govil, V., Aly, R., Ahmad, S.A. Phase III management of papulopustular rosacea with 2% green tea extract (-) EGCg in a hydrophilic cream: A placebo-controlled, double-blind study. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P108.
38. Syed, T., Aly, R., Benipoor, S., Ahmad, S.A. Management of seborrheic dermatitis with 2% analogue of green tea extract (-EGCg) in a hydrophilic cream: A placebo-controlled, double-blind study. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P812.
39. Ortonnne, J.-P., Reich, K., Sterry, W. Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFalpha monoclonal antibody, in patients with moderate-to-severe-chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P21.
40. Syed, T., Ahmad, S.A., Aly, R., Govil, V. Phase II management of vitiligo with 5% polyphenone (-EGCg) in a hydrophilic cream: A placebo-controlled, double-blind study. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P2605.
41. Sattler, G., Habbema, L. An open-label trial of 50 patients with bilateral nasolabial folds treated with a novel formulation of hyaluronic acid 28 mg/ml with lidocaine 0.3%. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P1037.
42. Hanke, C.W., Brandt, F., Coleman, W.P. III., Glaser, D.A. Effectiveness and durability of a hyaluronic acid 28 mg/ml, lidocaine 0.3% stable combination product as demonstrated in a multicenter, randomized trial. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P1040.
43. Hunt, R.H., Armstrong, D., Yaghoobi, M. et al. AGN 201904-Z (AGN), a novel enteric-coated PPI, produces greater, more prolonged acid suppression than esomeprazole (ESO) in healthy male volunteers. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 149.
44. Cools, M., Cauwenbergh, G., Vanhoutte, F. Tolerability, safety, and pharmacokinetics of single and multiple oral dosages of R115866 in healthy volunteers. J Am Acad Dermatol 2007, 56(2, Suppl. 2): Abst P2782.